Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Drugs Prevention-and-treatment-of-amyloidogenic-disease

 Growth differentiation factor-8 transgenic mice
The present invention provides a cell growth and differentiation factor, GDF-8, a polynucleotide ...


 Method for using phagocytic particles and ATP receptors to deliver antigens to MHC class I receptors to induce immunity against microbial pathogens or tumors or to suppress immunity
OF THE INVENTION This invention provides a method of delivering an antigen to an Class I MHC ...


 Modulation of cholesteryl ester transfer protein (CETP) activity
The invention claimed is: 1. A method for treating or preventing atherosclerosis in a human or ...


 Nucleic acids, vectors and host cells encoding heregulin
In accordance with the objects of this invention, we have identified and isolated novel ligand ...


 Immunoreactive peptides from Epstein-Barr virus
What is claimed is: 1. A polypeptide consisting of an amino acid sequence having the formula: (.phi....


 DNA encoding stationary phase, stress response sigma factor from Mycobacterium tuberculosis
OF THE INVENTION It is a discovery of the present invention that entry of M. tuberculosis into a ...


 Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
The present invention provides, among other things, a method of removing virus from a sample. The ...


 .alpha.-.beta. C4BP-type recombinant heteromultimeric proteins
The object of the present invention is therefore to develop recombinant soluble heteromultimeric ...


 Semi-refined carrageenan
The present invention provides methods for preparing a carrageenan product comprising the steps of ...


 Method for improving genetic stability of foreign insert nucleotide sequence in recombinant poliovirus
To be free from shortcomings of the poliovirus vector systems, in particular, genetic instability ...


 Prevention and treatment of amyloidogenic disease

Details
Inventors: Schenk, Dale B.;
Assignee: Neuralab Limited (BM)
Primary Examiner: Kunz; Gary
Assistant Examiner: Nichols; Christopher James
Attorney, Agent or Firm: Townsend and Townsend and Crew LLP

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

DETAILED DESCRIPTION I.
General Several amyloidogenic diseases and conditions are characterized by presence of deposits of A.
beta.
peptide aggregated to an insoluble mass in the brain of a patient.
Such diseases include Alzheimer's disease, Down's syndrome and cognitive impairment.
The latter is a symptom of Alzheimer's disease and Down's syndrome but can also without other characteristics of either of these diseases.
For example, mild cognitive impairment or age-associated memory loss occurs in some patient who have not yet developed, or may never develop full Alzheimer's disease.
Mild cognitive impairment can be defined by score on the Mini-Mental State Exam in accordance with convention.
Such diseases are characterized by aggregates of A.
beta.
that have a .
beta.
-pleated sheet structure and stain with Congo Red dye.
The basic approach of preventing or treating Alzheimer's disease or other amyloidogenic diseases by generating an immunogenic response to a component of the amyloid deposit in a patient is described in WO 99/27944 (incorporated by reference).
The present application reiterates and confirms the efficacy of the basic approach.
The present application is, however, principally directed to improved reagents and methods.
These improvements are premised, in part, on the present inventors having localized the preferred epitopes within A.
beta.
against which an immunogenic response should be directed.
The identification of preferred epitopes within A.
beta.
results in agents and methods having increased efficacy, reduced potential for side effects, and/or greater ease of manufacture, formulation and administration.
II.
Therapeutic Agents An immunogenic response can be active, as when an immunogen is administered to induce antibodies reactive with A.
beta.
in a patient, or passive, as when an antibody is administered that itself binds to A.
beta.
in a patient.
1.
Agents Inducing Active Immune Response Therapeutic agents induce an immunogenic response specifically directed to certain epitopes within A



Related patents
  HIV vaccine
What is claimed is: 1. A recombinant human immunodeficiency virus-1 (HIV-1), wherein the natural signal sequence (NSS) of the HIV-1 envelope glycoprotein gp120 of the ...
  Isolated nucleic acid encoding seven transmembrane receptors
The present invention is illustrated by the following examples relating to the isolation of human genomic and cDNA sequences encoding the novel 7TM receptors herein ...
  TIE-2 ligands, methods of making and uses thereof
What is claimed is: 1. An isolated antibody which specifically binds a ligand wherein the ligand consists of the amino acid sequence of SEQ ID NO: 2. 2. The antibody of ...
  Phthalidyl-isoquinoline derivatives
We claim: 1. A compound of the formula ##STR6## wherein each of R.sub.1, R.sub.2, R.sub.4, R.sub.5 and R.sub.6 is lower alkoxy; R.sub.3 is hydrogen or lower alkoxy; and R...
  Immune suppressive product
What is claimed is: 1. An oral vaccine, wherein said vaccine comprises a composition wherein said composition comprises a non-antibody fraction of milk and wherein said ...
  Anti-allergy anti-inflammatory composition
OF THE INVENTION The following unique features of Nimesulide may prove to be quite beneficial in all allergic disorders. 1) Nimesulide is a potent stabilizer of mast ...
  Dermatophagoides nucleic acid molecules, proteins and uses thereof
OF THE INVENTION The present invention provides for isolated proteins having molecular weights ranging from about 60 kilodaltons (kD) to about 109 kD, that include at ...
  Stabilized primate lentivirus envelope glycoproteins
OF THE INVENTION We have discovered a series of novel polypeptides that can (1) enhance the immunogenicity of primate lentivirus envelope proteins for certain conserved ...
  Endothelial-monocyte activating polypeptide III antibodies
What is claimed is: 1. An isolated antibody or fragment thereof that specifically binds to a protein whose amino acid sequence consists of amino acid residues 1 to 168 ...
  Bacillus thuringiensis toxins active against scarab pests
We claim: 1. An isolated polynucleotid encoding a toxin which is active against scarab pests, said polynucleotide encoding the amino acid sequence of SEQ ID NO. 4 or a ...

0.014

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved